Reported 2 days ago
The FDA has fully approved Novavax, Inc.'s COVID-19 vaccine with significant restrictions, allowing its use only for adults aged 65 and older and certain individuals aged 12-64 with underlying health conditions. This follows uncertainty surrounding the vaccine's approval process and skepticism from US Health Secretary Robert F. Kennedy Jr. The Novavax vaccine is unique as the only protein-based option in the U.S., amidst fully approved mRNA vaccines from Pfizer and Moderna. Despite challenges, Novavax reported strong first-quarter earnings, showcasing substantial revenue growth.
Source: YAHOO